Previous Treated Metastatic Non-small Cell Lung Cancer
Conditions
Keywords
Pemetrexed, Gefitinib, iressa, alimta
Brief summary
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
Interventions
DRUGGefitinib
compare progression free survivla rate and safety to both drugs
DRUGPemetrexed
compare PFS rate, safety to both drugs
Sponsors
Gachon University Gil Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients * second line * ECOG 0～2 * Patients with normal liver function and renal function
Exclusion criteria
* Patients with severe acute infection requiring antibiotic therapy * Patients who have received treatment in other areas of cancer within 5 years * During pregnancy and lactation patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | 5 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival | 5years |
Other
| Measure | Time frame |
|---|---|
| Number of participants with adverse events | 5years |
Countries
South Korea
Outcome results
None listed